<DOC>
	<DOC>NCT02372084</DOC>
	<brief_summary>To assess the pharmacokinetics of a single oral dose of osilodrostat (LCI699) 30 mg in subjects with mild, moderate and severe hepatic impairment compared with subjects with normal hepatic function.</brief_summary>
	<brief_title>A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Weight ≥50 kg and BMI between 1838kg/m2. Stable liver cirrhosis and evidence of hepatic impairment. ‐Free of significant medical disorders unrelated to underlying hepatic impairment History of any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs Subjects with ongoing alcohol or drug abuse Symptoms or history of encephalopathy (Grade 2 or above) History or presence of liver disease or liver injury (healthy volunteers only) History or presence of impaired renal function Clinical evidence of severe ascites. Total Bilirubin &gt; 6 mg/dL, Subjects with a serum free cortisol test results that is below the lower limit of normal (based on central laboratory) during the screening period Concomitant use of a drug that is a strong inducer of the CYP3A4/5 pathway Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatic impairment,</keyword>
	<keyword>osilodrostat,</keyword>
	<keyword>LCI699</keyword>
</DOC>